Brugada-like electrocardiogram pattern: how to stratify the risk for sudden cardiac death. Is sports activity contraindicated?

Journal of Cardiovascular Medicine
Pietro DeliseManuela Bocchino

Abstract

Brugada syndrome is associated with a considerable risk of sudden death in young and otherwise healthy adults. The syndrome is estimated to be responsible for at least 4% of all sudden deaths and at least 20% of sudden deaths in patients with structurally normal hearts. The diagnosis of Brugada syndrome is based on peculiar electrocardiogram (ECG) abnormalities classified by the European Society of Cardiology in three types: type 1 (coved-type) is the diagnostic pattern; type 2 (saddle-back type); and type 3 are considered significant if there is a conversion to a type 1, spontaneously or during administration of class I A/C anti-arrhythmic drugs (flecainide, etc.). There is a general agreement about the high risk of sudden death in patients with previous cardiac arrest, for whom an implantable defibrillator (ICD) is recommended. In contrast, controversy exists on the correct clinical behaviour in individuals without a history of previous cardiac arrest. To stratify the risk in patients with type 1 pattern, three major factors have been suggested: typical ECG pattern in the basal state; a history of syncope; and inducible ventricular tachycardia/ventricular fibrillation during electrophysiological study (EPS). However, the indi...Continue Reading

References

Dec 1, 1989·American Heart Journal·B MartiniS Dalla Volta
Feb 6, 1999·Journal of the American College of Cardiology·I GussakB R Chaitman
Jun 27, 2000·The American Journal of Cardiology·J S HermidaJ C Quiret
Mar 10, 2001·Journal of Cardiovascular Electrophysiology·C Antzelevitch
Mar 10, 2001·European Heart Journal·M BiancoP Zeppilli
Aug 31, 2001·Journal of the American College of Cardiology·Y MiyasakaT Iwasaka
Oct 17, 2002·Journal of Cardiovascular Electrophysiology·Maurizio GaspariniCarlo Ceriotti
Oct 17, 2002·Journal of Cardiovascular Electrophysiology·Máximo Rivero AyerzaPedro Brugada
Nov 6, 2002·Circulation·Arthur A M WildeUNKNOWN Study Group on the Molecular Basis of Arrhythmias of the European Society of Cardiology
May 28, 2003·Journal of the American College of Cardiology·Charles AntzelevitchKolawanee Nademanee
Jun 5, 2003·Journal of Cardiovascular Electrophysiology·Pedro BrugadaJosep Brugada
Jul 11, 2003·Archives des maladies du coeur et des vaisseaux·A LeenhardtB Cauchemez
Dec 10, 2003·Journal of the American College of Cardiology·Domenico CorradoGaetano Thiene
Dec 18, 2003·Journal of Cardiovascular Electrophysiology·Mohamed Chahine
Jun 17, 2005·Heart·J Boullin, J M Morgan

❮ Previous
Next ❯

Citations

Aug 20, 2008·Cases Journal·Jan Paul M FrölkeJoep Lrm Smeets

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.